It's imperative to identify more HIV-infected women earlier in pregnancy through HIV testing and to reduce mother-to-child transmission of the virus that causes AIDS.
Of course, managing HIV-infected pregnant women doesn't stop with antiretroviral therapy. Patient counseling about treatment before, during, and after childbirth is also critical. And although treating pregnant women and their infants with zidovudine (ZDV) has significantly reduced perinatal transmission of HIV, many potentially preventable infections still occur.
HIV testing The risk of perinatal transmission of HIV-1 has been reduced from 25% to less than 2% for a woman who is aware of her HIV infection early in pregnancy, thanks to antiretroviral therapy and appropriate obstetric intervention. Ideally, ob/gyns should offer all women an HIV test during the first prenatal visit so that those who test positive can begin treatment. The CDC recommends offering all pregnant women voluntary HIV testing not only then, but again to those who initially refuse testing. Also consider repeat testing of high-risk women in the third trimester.
Clinical trial data show that antiretroviral prophylaxis can reduce transmission by up to 50%, even when it's delayed until delivery and given to the newborn 4 To help the greatest number of newborns, routinely offer rapid HIV testing to women whose status is unknown during labor to reduce transmission even among women who wait to seek care until the onset of labor. The rapid HIV test kits now licensed in the US allow test results to be available in less than 20 minutes. Results from the OraQuick Rapid HIV-1 Antibody Test (OraSure Technologies Inc., Bethlehem, Pa.) can be read within 20 to 40 minutes and results from the Reveal Rapid HIV-1 Antibody Test (MedMira Labs Inc., Halifax, Nova Scotia) can be read in roughly 5 to 10 minutes.
Early preterm birth risk linked to low PlGF levels during pregnancy screening
November 20th 2024New research highlights that low levels of placental growth factor during mid-pregnancy screening can effectively predict early preterm birth, offering a potential tool to enhance maternal and infant health outcomes.
Read More
Major congenital malformations not linked to first trimester tetracycline use
November 20th 2024A large population-based study found that first-trimester tetracycline exposure does not elevate the risk of major congenital malformations, though specific risks for nervous system and eye anomalies warrant further research.
Read More
No link found between prenatal cannabis use and childhood developmental delay
November 5th 2024In a recent study, offspring of women with cannabis use in early pregnancy confirmed by self-report or toxicology test were not at an increased risk of childhood early developmental delay up to the age of 5.5 years.
Read More